Anocca raises $36.6M for large-scale development of cancer cell therapies

Published on June 15, 2023

Anocca AB has raised SEK 400 million ($36.6 million) to further develop the discovery and manufacture of next generation cell therapies for cancer on an industrial scale. It will also allow Anocca to progress its first products into clinical trials. The financing brings together a group of existing and new investors, including Mellby Gård, AMF, […]

The post Anocca raises $36.6M for large-scale development of cancer cell therapies appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Continue reading on website
Other news

ElevateBio raises $401M for cell and gene therapies

June 15, 2023
ElevateBio, LLC (ElevateBio), a technology-driven company focused on cell and gene therapies, has closed its $401 million Series D financing. “We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company. We are thrilled to welcome Khalil to our […]The post ElevateBio raises

Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

June 15, 2023
Gene therapy company Kate Therapeutics Inc. (KateTx), has emerged from stealth mode with a $51 million Series A financing. In addition, the company has granted Astellas Pharma Inc. an exclusive, worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM). There are a large number of genetically defined and complex muscle […]The post Kate Therapeu